L. Garraway

Author Correction: Comprehensive analysis of chromothripsis in 2,658 human cancers using whole-genome sequencing
20234 citationsauthor #414
Author Correction: Pan-cancer analysis of whole genomes
20238 citationsauthor #341
Abstract 5524: Persistent patient barriers to genomic testing in ambulatory oncology
20230 citationsauthor #22
Author Correction: Comprehensive molecular characterization of mitochondrial genomes in human cancers
20231 citationsauthor #359
Abstract C070: REAL variance in genomic testing by sex, age, race, ethnicity, and language: PROFILE database 7/2011 - 1/2022
20230 citationsauthor #21
Author Correction: Patterns of somatic structural variation in human cancer genomes
20234 citationsauthor #417
Author Correction: Pan-cancer analysis of whole genomes identifies driver rearrangements promoted by LINE-1 retrotransposition
20237 citationsauthor #448
Author Correction: Disruption of chromatin folding domains by somatic genomic rearrangements in human cancer
20231 citationsauthor #415
Author Correction: The evolutionary history of 2,658 cancers
20234 citationsauthor #413
Author Correction: Inferring structural variant cancer cell fraction
20220 citationsauthor #418
An activation to memory differentiation trajectory of tumor-infiltrating lymphocytes informs metastatic melanoma outcomes.
202248 citationsauthor #13
Genomic Correlates of Outcome in Tumor-Infiltrating Lymphocyte Therapy for Metastatic Melanoma.
202214 citationsauthor #11
Implementation of a prostate cancer‐specific targeted sequencing panel for credentialing of patient‐derived cell lines and genomic characterization of patient samples
20227 citationsauthor #21
Stepwise-edited, human melanoma models reveal mutations’ effect on tumor and microenvironment
202246 citationsauthor #19
Author Correction: Pathway and network analysis of more than 2500 whole cancer genomes
20222 citationsauthor #472
037 A systems immunology approach to classify melanoma tumor infiltrating lymphocytes (TILs) informs and models overall survival
20220 citationsauthor #13
Making cancer research more inclusive
20219 citationsauthor #3
Epitope spreading toward wild-type melanocyte-lineage antigens rescues suboptimal immune checkpoint blockade responses
202181 citationsauthor #25
CD38 in Advanced Prostate Cancers
202132 citationsauthor #92
A single-cell landscape of high-grade serous ovarian cancer
2020377 citationsauthor #27
Author Correction: Retrospective evaluation of whole exome and genome mutation calls in 746 cancer samples
20201 citationsauthor #449
Sex differences in oncogenic mutational processes
202091 citationsauthor #18
Abstract NG13: Metabolomic adaptations and correlates of survival to immune checkpoint blockade
20200 citationsauthor #19
Author Correction: Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma
202011 citationsauthor #31
Landscape of somatic single nucleotide variants and indels in colorectal cancer and impact on survival
202070 citationsauthor #29
Abstract PD2-09: The genomic landscape of intrinsic and acquired resistance to cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) in patients with hormone receptor-positive (HR+)/HER2- metastatic breast cancer (MBC)
20203 citationsauthor #19
Abstract B23: Genomic sequencing of metastatic hormone-receptor positive breast cancer implicates AKT1 in driving resistance to cyclin-dependent kinase 4/6 inhibitors
20201 citationsauthor #9
Patterns of somatic structural variation in human cancer genomes
2020686 citationsauthor #417
Retrospective evaluation of whole exome and genome mutation calls in 746 cancer samples
202045 citationsauthor #449
The genomic landscape of intrinsic and acquired resistance to cyclin-dependent kinase 4/6 inhibitors in patients with hormone receptor positive metastatic breast cancer.
2020126 citationsauthor #27
Abstract PD9-02: Evolutionary analysis of 462 serial metastatic biopsies from 208 patients with estrogen receptor-positive (ER+) metastatic breast cancer (MBC) using whole exome sequencing (WES)
20192 citationsauthor #22
A Functional Landscape of Resistance to MEK1/2 and CDK4/6 Inhibition in NRAS-Mutant Melanoma.
201935 citationsauthor #10
Abstract LB-113: MAPK pathway suppression unmasks latent DNA repair defects and confers a chemical synthetic vulnerability inBRAF,NRASandNF1-mutant melanomas
20190 citationsauthor #11
The landscape of cancer cell line metabolism
2019430 citationsauthor #25
Publisher Correction: The long tail of oncogenic drivers in prostate cancer
20190 citationsauthor #26
Synthetic lethality as an engine for cancer drug target discovery
2019382 citationsauthor #2
Abstract SY45-04: Development of therapeutic strategies by resolving the tumor ecosystem
20190 citationsauthor #20
Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma
2019770 citationsauthor #31
Abstract A082: Single-cell RNA-sequencing of metastatic melanoma identifies a cancer cell-intrinsic program associated with immune checkpoint inhibitor resistance
20190 citationsauthor #49
Metabolomic adaptations and correlates of survival to immune checkpoint blockade
2019199 citationsauthor #19
The genomic landscape of intrinsic and acquired resistance to cyclin-dependent kinase 4/6 inhibitors in patients with hormone receptor positive metastatic breast cancer
2019163 citationsauthor #27
Next-generation characterization of the Cancer Cell Line Encyclopedia
20192,680 citationsauthor #67
Pooled Genomic Screens Identify Anti-apoptotic Genes as Targetable Mediators of Chemotherapy Resistance in Ovarian Cancer
201940 citationsauthor #27
Publisher Correction: The long tail of oncogenic drivers in prostate cancer
20199 citationsauthor #26
MAPK Pathway Suppression Unmasks Latent DNA Repair Defects and Confers a Chemical Synthetic Vulnerability in BRAF-, NRAS-, and NF1-Mutant Melanomas.
201976 citationsauthor #11
Abstract AP14: POOLED GENOMIC SCREENS IDENTIFY ANTI-APOPTOTIC GENES AS MEDIATORS OF CHEMOTHERAPY RESISTANCE IN OVARIAN CANCER
20190 citationsauthor #24
Genomic Evolutionary Patterns of Leiomyosarcoma and Liposarcoma
201922 citationsauthor #17
Ex Vivo Profiling of PD-1 Blockade Using Organotypic Tumor Spheroids.
2018455 citationsauthor #78
Genetic Mechanisms of Immune Evasion in Colorectal Cancer.
2018117 citationsauthor #47
Molecular Genetics of Melanocytic Neoplasia
20183 citationsauthor #2
Binding of TMPRSS2-ERG to BAF Chromatin Remodeling Complexes Mediates Prostate Oncogenesis.
201895 citationsauthor #13
Abstract 1224: Deep targeted tumor sequencing of colorectal cancer cases to study associations of molecular subtypes with clinical, genetic, and lifestyle risk factors
20180 citationsauthor #16
Real-time Genomic Characterization of Advanced Pancreatic Cancer to Enable Precision Medicine.
2018287 citationsauthor #47
Single-cell RNA-sequencing and -imaging of melanoma ecosystems reveals sources of resistance to immune checkpoint blockade.
20181 citationsauthor #16
Approaches to carrier testing and results disclosure in translational genomics research: The clinical sequencing exploratory research consortium experience
201813 citationsauthor #23
6-Phosphogluconate Dehydrogenase Links Cytosolic Carbohydrate Metabolism to Protein Secretion
201818 citationsauthor #6
Increased Tumor Glycolysis Characterizes Immune Resistance to Adoptive T Cell Therapy.
2018518 citationsauthor #27
TIME (Tumor Immunity in the MicroEnvironment) classification based on tumor CD274 (PD-L1) expression status and tumor-infiltrating lymphocytes in colorectal carcinomas
201858 citationsauthor #20
Abstract 3254: Dissecting genomic determinants of response to platinum-based chemotherapy in advanced NSCLC and colorectal cancer
20180 citationsauthor #7
Abstract PR03: Genetic mechanisms of immune evasion in colorectal cancer
2018293 citationsauthor #47
The long tail of oncogenic drivers in prostate cancer
2018723 citationsauthor #26
A Convergence-Based Framework for Cancer Drug Resistance.
2018216 citationsauthor #3
Randomized trial of 10 days of decitabine ± bortezomib in untreated older patients with AML: CALGB 11002 (Alliance).
201845 citationsauthor #15
Whole exome sequencing (WES) in hormone-receptor positive (HR+) metastatic breast cancer (MBC) to identify mediators of resistance to cyclin-dependent kinase 4/6 inhibitors (CDK4/6i).
201812 citationsauthor #12
Abstract 571: Meta-analysis of genomic predictors of response to immune checkpoint therapy in metastatic melanoma
20170 citationsauthor #8
Prostate cancer-associated SPOP mutations confer resistance to BET inhibitors through stabilization of BRD4
2017283 citationsauthor #24
065 Highly conserved tissue immune signatures are co-opted in cancer
20170 citationsauthor #9
Defining a Cancer Dependency Map.
20172,525 citationsauthor #21
Abstract PR01:Fusobacterium nucleatumand mutational landscape of colorectal cancer in whole-exome sequencing analysis
20171 citationsauthor #13
Abstract B44: Emerging targets from Cancer Dependency Map v0.1
20170 citationsauthor #15
Abstract A02: Expanding tumor chemical-genetic interaction map using next-generation cancer models
20170 citationsauthor #15
Scalable whole-exome sequencing of cell-free DNA reveals high concordance with metastatic tumors
20171 citationsauthor #51
Opposing effects of cancer type-specific SPOP mutations on BET protein degradation and sensitivity to BET inhibitors
2017160 citationsauthor #27
Erratum to: Unraveling the clonal hierarchy of somatic genomic aberrations
20170 citationsauthor #9
Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden
201711 citationsauthor #21
Cell-free tumor DNA and TERT promoter mutations in bladder cancer.
20172 citationsauthor #13
Abstract MIP-075: SOMATIC MUTATIONS AND COPY-NUMBER VARIATIONS IN OVARIAN CANCERS VIA TARGETED SEQUENCING OF EXONS OF 300 CANCER-ASSOCIATED GENES, INCLUDING MULTIPLE DNA DAMAGE REPAIR GENES
20170 citationsauthor #3
Assigning clinical meaning to somatic and germ-line whole-exome sequencing data in a prospective cancer precision medicine study
201746 citationsauthor #41
Label-free longitudinal monitoring of melanogenesis in the evolution of melanoma treatment resistance (Conference Presentation)
20170 citationsauthor #4
Abstract S1-01: Whole exome and transcriptome sequencing of resistant ER+ metastatic breast cancer
201713 citationsauthor #19
Clinical actionability of germline testing in patients with limited colorectal polyps.
20170 citationsauthor #12
Abstract 1564: A computational framework for removing mouse contamination in tumors sequenced from patient-derived xenografts
20170 citationsauthor #4
Exome Sequencing of African-American Prostate Cancer Reveals Loss-of-Function ERF Mutations.
2017119 citationsauthor #31
Systematic genomic and translational efficiency studies of uveal melanoma
201732 citationsauthor #21
Abstract 3037: Dissecting treatment resistance in patients with ovarian cancer and PDX-models using single-cell RNA-sequencing
20170 citationsauthor #11
The long tail of significantly mutated genes in prostate cancer.
20171 citationsauthor #9
Genomic profiling of ER+ breast cancers after short-term estrogen suppression reveals alterations associated with endocrine resistance
2017105 citationsauthor #31
Characterizing reduced coverage regions through comparison of exome and genome sequencing data across ten centers
201731 citationsauthor #29
Abstract 3036: Real-time genomic characterization of metastatic pancreatic cancer to enable precision medicine
20171 citationsauthor #35
Abstract PR02: Towards a Cancer Dependency Map
20171 citationsauthor #15
Abstract B17: Identification of Druggable Targets through Functional Multi-Omics in Renal Medullary Carcinoma
20170 citationsauthor #17
Abstract 1010: Genomic analysis of recurrent ovarian cancer in patient-derived xenografts treated with platinum and taxane chemotherapy
20170 citationsauthor #8
Future cancer research priorities in the USA: a Lancet Oncology Commission.
2017162 citationsauthor #23
062 Human melanoma TILs share phenotypic and transcriptional properties with tissue resident memory T cells
20170 citationsauthor #9
Abstract 1286: Targeted deep sequencing of colorectal tumor tissues to study associations of tumor subtypes with germline genetic, lifestyle, and environmental risk factors
20170 citationsauthor #38
Abstract 5561: Single-cell analysis reveals an adaptive, transiently heritable, slowly-dividing, drug-resistant state inhibitable by drug combinations
20170 citationsauthor #7
Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden
20172,910 citationsauthor #21
Abstract 5647: Intron retention as a novel source of tumor neoantigens associated with response to checkpoint inhibitor therapy
20170 citationsauthor #10
Enrichment of germline DNA-repair gene mutations in patients with colorectal cancer.
20172 citationsauthor #10
Abstract B15: Comprehensive cistromic characterization of SOX10, a lineage-specific genetic dependency in melanoma, via the integration of functional genomic approaches
20170 citationsauthor #6

PROFILE

PAPERS

TIMELINE

COAUTHOR MAP

CONCEPT FOOTPRINT